First Time Loading...

Luye Pharma Group Ltd
HKEX:2186

Watchlist Manager
Luye Pharma Group Ltd Logo
Luye Pharma Group Ltd
HKEX:2186
Watchlist
Price: 3.02 HKD Market Closed
Updated: May 5, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

6.1B
+2%
Revenue
Growth Rates:
1 Year
+3%
3 Years
+11%
5 Years
+19%
7 Years
-
10 Years
-
1.3B
+97%
Operating Income
Growth Rates:
1 Year
+42%
3 Years
+9%
5 Years
-15%
7 Years
-
10 Years
-
532.6m
+16%
Net Income
Growth Rates:
1 Year
-12%
3 Years
-25%
5 Years
-59%
7 Years
-
10 Years
-

Earnings Waterfall
Luye Pharma Group Ltd

Revenue
6.1B CNY
Cost of Revenue
-1.9B CNY
Gross Profit
4.2B CNY
Operating Expenses
-2.9B CNY
Operating Income
1.3B CNY
Other Expenses
-764.9m CNY
Net Income
532.6m CNY

Income Statement
Luye Pharma Group Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2005 Mar-2006 Jun-2006 Sep-2006 Dec-2006 Mar-2007 Jun-2007 Sep-2007 Dec-2007 Mar-2008 Jun-2008 Sep-2008 Dec-2008 Mar-2009 Jun-2009 Sep-2009 Dec-2009 Mar-2010 Jun-2010 Sep-2010 Dec-2010 Mar-2011 Jun-2011 Sep-2011 Dec-2011 Mar-2012 Jun-2012 Jun-2017 Dec-2017 Jun-2018 Dec-2018 Jun-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023
Revenue
Revenue
344
N/A
350
+2%
335
-4%
328
-2%
308
-6%
339
+10%
390
+15%
442
+13%
509
+15%
527
+3%
562
+7%
608
+8%
651
+7%
714
+10%
792
+11%
876
+11%
955
+9%
1 075
+13%
1 177
+9%
1 289
+10%
1 341
+4%
1 404
+5%
1 480
+5%
1 581
+7%
1 774
+12%
1 926
+9%
2 010
+4%
1 851
-8%
3 815
+106%
4 168
+9%
5 173
+24%
6 101
+18%
6 358
+4%
6 189
-3%
5 540
-10%
5 529
0%
5 200
-6%
5 099
-2%
5 982
+17%
6 035
+1%
6 143
+2%
Gross Profit
Cost of Revenue
(76)
(72)
(68)
(67)
(64)
(69)
(75)
(78)
(80)
(75)
(75)
(76)
(86)
(93)
(111)
(130)
(136)
(154)
(163)
(165)
(204)
(222)
(231)
(273)
(301)
(323)
(346)
(424)
(851)
(874)
(1 124)
(1 376)
(1 479)
(1 544)
(1 549)
(1 783)
(1 803)
(1 606)
(1 841)
(2 001)
(1 939)
Gross Profit
268
N/A
278
+4%
266
-4%
261
-2%
245
-6%
270
+10%
315
+17%
364
+16%
429
+18%
451
+5%
487
+8%
532
+9%
565
+6%
621
+10%
681
+10%
746
+9%
819
+10%
922
+13%
1 014
+10%
1 124
+11%
1 137
+1%
1 182
+4%
1 249
+6%
1 308
+5%
1 473
+13%
1 603
+9%
1 664
+4%
1 426
-14%
2 963
+108%
3 293
+11%
4 049
+23%
4 725
+17%
4 879
+3%
4 645
-5%
3 991
-14%
3 746
-6%
3 397
-9%
3 493
+3%
4 141
+19%
4 034
-3%
4 204
+4%
Operating Income
Operating Expenses
(175)
(182)
(175)
(172)
(164)
(185)
(227)
(273)
(352)
(377)
(414)
(456)
(477)
(520)
(559)
(606)
(664)
(739)
(801)
(896)
(953)
(1 013)
(1 094)
(1 150)
(1 253)
(1 364)
(1 418)
(990)
(1 873)
(2 024)
(2 529)
(2 954)
(3 136)
(2 963)
(2 801)
(2 823)
(2 961)
(3 442)
(3 224)
(3 376)
(2 907)
Selling, General & Administrative
(167)
(171)
(162)
(158)
(162)
(183)
(226)
(267)
(324)
(346)
(381)
(423)
(446)
(486)
(522)
(565)
(610)
(682)
(747)
(835)
(874)
(917)
(974)
(1 011)
(1 132)
(1 235)
(1 282)
(878)
(1 709)
(1 787)
(2 117)
(2 448)
(2 560)
(2 419)
(2 181)
(2 116)
(2 271)
(2 327)
(2 403)
(2 711)
(2 700)
Research & Development
0
0
0
0
0
0
0
0
0
(6)
(13)
(22)
(37)
(40)
(45)
(51)
(60)
(66)
(72)
(86)
(85)
(98)
(113)
(124)
(135)
(142)
(148)
0
(289)
0
(491)
0
(711)
0
(790)
0
(683)
0
(857)
0
0
Depreciation & Amortization
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(3)
0
(4)
0
(4)
0
(5)
0
(5)
0
0
0
0
Other Operating Expenses
(9)
(11)
(14)
(14)
(3)
(2)
(1)
(6)
(28)
(24)
(20)
(11)
7
6
7
10
6
9
18
25
5
3
(7)
(15)
14
13
12
(112)
127
(237)
83
(507)
139
(544)
174
(707)
(2)
(1 114)
36
(666)
(207)
Operating Income
93
N/A
96
+3%
92
-4%
90
-2%
81
-10%
84
+5%
89
+5%
92
+3%
77
-16%
74
-4%
73
-1%
77
+5%
89
+15%
101
+14%
122
+21%
140
+15%
155
+11%
182
+18%
212
+17%
228
+7%
183
-20%
169
-8%
155
-9%
158
+2%
220
+39%
239
+9%
246
+3%
436
+77%
1 090
+150%
1 269
+16%
1 520
+20%
1 771
+16%
1 743
-2%
1 682
-4%
1 190
-29%
924
-22%
436
-53%
51
-88%
917
+1 681%
657
-28%
1 297
+97%
Pre-Tax Income
Interest Income Expense
(3)
(0)
1
4
5
4
(2)
(7)
(11)
(11)
(7)
(3)
(1)
(0)
2
7
12
11
6
(0)
(16)
(17)
(23)
(27)
(19)
(28)
(29)
25
28
60
(34)
(87)
(98)
(215)
(246)
(177)
(248)
(239)
(233)
(134)
(585)
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
0
(0)
(4)
(5)
(5)
(4)
(2)
(1)
(1)
(1)
(3)
28
28
28
30
(0)
(0)
(1)
0
(1)
0
(2)
(21)
10
0
0
0
(262)
0
(14)
0
(12)
Total Other Income
(0)
(0)
(1)
(1)
0
0
(0)
(0)
(1)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(11)
0
(21)
(12)
(2)
(0)
0
0
0
0
0
Pre-Tax Income
90
N/A
96
+6%
92
-4%
93
+1%
85
-8%
88
+3%
87
-1%
84
-3%
66
-22%
64
-3%
66
+4%
70
+6%
83
+18%
96
+16%
119
+24%
145
+22%
166
+15%
192
+15%
218
+13%
224
+3%
195
-13%
181
-8%
159
-12%
161
+1%
201
+25%
211
+5%
217
+3%
461
+113%
1 116
+142%
1 329
+19%
1 473
+11%
1 663
+13%
1 634
-2%
1 455
-11%
942
-35%
746
-21%
(75)
N/A
(188)
-152%
670
N/A
523
-22%
700
+34%
Net Income
Tax Provision
(0)
(0)
(1)
(3)
(5)
(7)
(9)
(11)
(8)
(7)
(8)
(10)
(21)
(28)
(36)
(40)
(37)
(44)
(50)
(53)
(45)
(42)
(39)
(41)
(35)
(34)
(25)
(73)
(136)
(173)
(167)
(225)
(280)
(256)
(239)
(175)
(70)
(62)
(86)
(98)
(161)
Income from Continuing Operations
90
95
91
91
81
82
78
74
58
56
58
60
62
68
83
105
129
148
167
172
150
139
121
120
166
177
192
388
981
1 156
1 306
1 438
1 354
1 199
703
571
(145)
(250)
583
425
539
Income to Minority Interest
(1)
(1)
(0)
0
3
3
3
3
1
0
0
0
0
0
0
0
(6)
(9)
(13)
(15)
(14)
(16)
(17)
(19)
(15)
(12)
(11)
(2)
1
3
(3)
34
42
5
3
(17)
10
26
22
32
(6)
Net Income (Common)
90
N/A
95
+5%
91
-4%
91
N/A
84
-8%
85
+2%
81
-5%
77
-5%
58
-24%
57
-3%
59
+4%
60
+3%
62
+3%
68
+9%
83
+23%
105
+27%
124
+17%
139
+12%
154
+11%
156
+1%
136
-13%
123
-10%
104
-15%
102
-2%
152
+49%
165
+9%
181
+10%
385
+112%
981
+155%
1 159
+18%
1 303
+12%
1 472
+13%
1 396
-5%
1 204
-14%
707
-41%
554
-22%
(134)
N/A
(224)
-67%
605
N/A
458
-24%
533
+16%
EPS (Diluted)
0.22
N/A
0.23
+5%
0.22
-4%
0.18
-18%
0.15
-17%
0.17
+13%
0.15
-12%
0.14
-7%
0.11
-21%
0.11
N/A
0.12
+9%
0.13
+8%
0.13
N/A
0.14
+8%
0.17
+21%
0.21
+24%
0.25
+19%
0.28
+12%
0.31
+11%
0.32
+3%
0.28
-13%
0.26
-7%
0.22
-15%
0.21
-5%
0.31
+48%
0.33
+6%
0.37
+12%
0.12
-68%
0.3
+150%
0.36
+20%
0.4
+11%
0.46
+15%
0.43
-7%
0.37
-14%
0.22
-41%
0.16
-27%
-0.04
N/A
-0.06
-50%
0.17
N/A
0.13
-24%
0.14
+8%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.